These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24121220)

  • 1. [Effectiveness of pentoxifylline and of bio-electromagnetic therapy in lower limb obliterative arterial disease].
    Bernát SI
    Orv Hetil; 2013 Oct; 154(42):1674-9. PubMed ID: 24121220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Secondary prevention and conservative therapy of obliterative arteriosclerosis].
    Landi A
    Orv Hetil; 2004 May; 145(20):1035-43. PubMed ID: 15202325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Lower Extremity Functioning in Peripheral Artery Disease: Exercise, Endovascular Revascularization, or Both?
    McDermott MM; Kibbe MR
    JAMA; 2017 Feb; 317(7):689-690. PubMed ID: 28241363
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial--walking distance and microcirculation.
    De Sanctis MT; Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Incandela L; Bucci M; Geroulakos G; Ramaswami G; Vasdekis S; Agus G; Bavera P; Ippolito E
    Angiology; 2002; 53 Suppl 1():S7-12. PubMed ID: 11865838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials.
    Shahin Y; Mazari F; Chetter I
    Int J Surg; 2011; 9(3):209-13. PubMed ID: 21195215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of cilostazol and pentoxifylline for treating intermittent claudication.
    Dawson DL; Cutler BS; Hiatt WR; Hobson RW; Martin JD; Bortey EB; Forbes WP; Strandness DE
    Am J Med; 2000 Nov; 109(7):523-30. PubMed ID: 11063952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication.
    de Albuquerque RM; Virgini-Magalhães CE; Lencastre Sicuro F; Bottino DA; Bouskela E
    Angiology; 2008; 59(5):549-58. PubMed ID: 18388031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of supervised exercise therapy for intermittent claudication on lower limb lean mass.
    Vun SV; Miller MD; Delaney CL; Allan RB; Spark JI
    J Vasc Surg; 2016 Dec; 64(6):1763-1769. PubMed ID: 27633168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
    Guest JF; Davie AM; Clegg JP
    Curr Med Res Opin; 2005 Jun; 21(6):817-26. PubMed ID: 15969881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs.
    Chacón-Quevedo A; Eguaras MG; Calleja F; Garcia MA; Roman M; Casares J; Muñoz I; Concha M
    Angiology; 1994 Jul; 45(7):647-53. PubMed ID: 8024164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Placebo-controlled double-blind study of the effectiveness of Ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication].
    Blume J; Kieser M; Hölscher U
    Vasa; 1996; 25(3):265-74. PubMed ID: 8967154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-range intermittent claudication and rest pain: microcirculatory effects of pentoxifylline in a randomized, controlled trial.
    Incandela L; De Sanctis MT; Cesarone MR; Belcaro G; Nicolaides AN; Geroulakos G; Ramaswami G
    Angiology; 2002; 53 Suppl 1():S27-30. PubMed ID: 11865832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly.
    Ciocon JO; Galindo-Ciocon D; Galindo DJ
    Angiology; 1997 Mar; 48(3):237-40. PubMed ID: 9071199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial.
    Peters H; Kieser M; Hölscher U
    Vasa; 1998 May; 27(2):106-10. PubMed ID: 9612115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis.
    Girolami B; Bernardi E; Prins MH; Ten Cate JW; Hettiarachchi R; Prandoni P; Girolami A; Büller HR
    Arch Intern Med; 1999 Feb; 159(4):337-45. PubMed ID: 10030306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication.
    Dawson DL; Zheng Q; Worthy SA; Charles B; Bradley DV
    Angiology; 2002; 53(5):509-20. PubMed ID: 12365857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease.
    Meng Y; Squires H; Stevens JW; Simpson E; Harnan S; Thomas S; Michaels J; Stansby G; O'Donnell ME
    Angiology; 2014 Mar; 65(3):190-7. PubMed ID: 23378195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of iloprost in patients with intermittent claudication.
    Creager MA; Pande RL; Hiatt WR
    Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [POSSIBILITIES OF THE FORCED INTRAARTERIAL INJECTION OF MEDICINAL PREPARATIONS IN A COMPLEX OF TREATMENT FOR THE LOWER EXTREMITIES CHRONIC ISCHEMIA].
    Sander SV
    Klin Khir; 2017; (2):62-5. PubMed ID: 30273457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a long-term exercise program on lower limb mobility, physiological responses, walking performance, and physical activity levels in patients with peripheral arterial disease.
    Crowther RG; Spinks WL; Leicht AS; Sangla K; Quigley F; Golledge J
    J Vasc Surg; 2008 Feb; 47(2):303-9. PubMed ID: 18241753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.